Key result
Immunization with the chimeric spike antigen CoVEXS5 elicited broadly cross-reactive neutralizing antibodies and protected mice and hamsters from clinical disease and viral replication after challenge with diverse SARS-CoV-2 variants.
Why the study?
Next-generation vaccines are required to address the evolving nature of SARS-CoV-2 and to protect against emerging pandemic threats from other coronaviruses by eliciting broad protection.
A novel chimeric spike antigen vaccine (CoVEXS5) demonstrates broad pan-sarbecovirus immunity and protection against variants like Omicron XBB.1.5 in preclinical models.
Answers are grounded in this paper and cite their sources.
Supports chimeric spike vaccine development for broad sarbecovirus protection; leaves open translation to human efficacy and safety.
Next-generation vaccines are required to address the evolving nature of SARS-CoV-2 and to protect against emerging pandemic threats from other coronaviruses. These vaccines should aim to elicit broad-protection, provide long-lasting immunity and facilitate equitable access for all populations. In this study, a panel of chimeric, full-length spike antigens were developed that incorporate mutations from previous, circulating and predicted SARS-CoV-2 variants. The lead candidate (CoVEXS5) was obtained from a high-yield production process in stable CHO cells with purity of >95%, long-term stability and elicitation of broadly cross-reactive neutralising antibodies when delivered to mice in a squalene emulsion adjuvant (Sepivac SWE™). In both mice and hamsters, CoVEXS5 immunisation reduced clinical disease signs, lung inflammation and organ viral titres after SARS-CoV-2 infection, including challenge with the highly immunoevasive Omicron XBB.1.5 subvariant. In mice previously primed with a licenced protein vaccine (NVX-CoV2373), CoVEXS5 could boost T cell immunity, as well as neutralising antibodies levels against viruses from three sarbecoviruses clades. The breadth of sarbecovirus cross-reactivity elicited by CoVEXS5 exceeded that observed after boosting with the NVX-CoV2373 vaccine. These findings highlight the potential of a chimeric spike antigen, formulated in an open-access adjuvant, as a next-generation vaccine candidate to enhance cross-protection against emerging sarbecoviruses in vaccinated populations globally.
No takes yet. Share an insight, caveat, or question.
Counoupas et al. (2024) studied SARS-CoV-2 infection. CoVEXS5 (chimeric spike antigen CSA05 + Sepivac SWE adjuvant) vs. Sham (PBS) or Novavax NVX-CoV2373 was evaluated on Protection against clinical disease, weight loss, and viral replication after SARS-CoV-2 challenge. Immunization with the chimeric spike antigen CoVEXS5 elicited broadly cross-reactive neutralizing antibodies and protected mice and hamsters from clinical disease and viral replication after challenge with diverse SARS-CoV-2 variants.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: